April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Disease Activity of Adult Patients with a History of Juvenile Idiopathic Arthritis Associated Uveitis
Author Affiliations & Notes
  • Yufei Tu
    The Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, NJ
  • Sergio Schwartzman
    Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
  • David S Chu
    The Institute of Ophthalmology and Visual Science, New Jersey Medical School, Rutgers University, Newark, NJ
    Metropolitan Eye Research and Surgery Institute, Palisades Park, NJ
  • Footnotes
    Commercial Relationships Yufei Tu, None; Sergio Schwartzman, Abbvie (C), Amgen (C), Discus (C), Genentech (C), Hospira (C), Janssen (C), Pfizer (C), UCB (C); David Chu, Allergan (F), Bausch and Lomb (R), Genentech (F), Novartis (F), Santen (F), Xoma (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5325. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yufei Tu, Sergio Schwartzman, David S Chu; Disease Activity of Adult Patients with a History of Juvenile Idiopathic Arthritis Associated Uveitis. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5325.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To study whether uveitis activity subsides in patients with history of uveitis associated with juvenile idiopathic arthritis (JIA) as they become adults.

Methods: Retrospective chart review using the following criteria: patients with history of JIA and noninfectious uveitis; at lease one office visit at age equal or greater than 17 years.

Results: 20 subjects were identified. 19 of 20 (95%) patients were female. Mean age at the final visit was 25.6 years (range, 17-43). Bilateral uveitis represents 17 cases (85%). There were 10 anterior uveitis (50%), 2 intermediate (10%), and 8 panuveitis (40%). 6 patients was inactive and medication-free (Group I) at the last visit (6/20, 30%). Among the rest (Group A), of 14 patients (70%), 3 patients had active disease with immunomodulatory therapy (IMT) or topical anti-inflammatory therapy and 11 patients (55%) were inactive with IMT. Among patients in I, average best-corrected logMAR visual acuity (BCVA) in the better eye was 0.07 at the final visit. For group A, the average BCVA in the better eye was 0.16. Among those patients, biologics including adalimumab and infliximab were used in 8 patients (8/14, 57%). Cataract (14, 70%) and glaucoma (8, 40%) were the most common complications of all patients. Among all patients, 8 (40%) had cataract surgery and 2 (10%) had glaucoma surgery.

Conclusions: Uveitis of most patients with history of JIA continues to be active or requires treatment through early to middle adulthood. Although the visual acuity among these patients is excellent, the need for cataract surgery among them is common.

Keywords: 746 uveitis-clinical/animal model • 557 inflammation • 432 autoimmune disease  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×